Glucose Monitoring

Researchers considered finding a diabetes drug that also produced a cardiovascular benefit to be a "holy grail."

A point of care medication delivery system improves medication adherence to cardiovascular medications without increasing costs.

The warnings will address 2 issues: the risk of too much acid in the blood and severe urinary tract infections.

The health benefits for participants of the Complete Health Improvement Program ("CHIP"), a lifestyle medicine program, are present regardless of the program tuition payment source.

The technique deploys several strategies to reduce cancer risk. It is being evaluated in mouse models but researchers are already looking ahead to human studies.

Recent emphasis of identifying those with prediabetes and intervening to halt its progression is aimed at reducing the financial impact of diabetes in the United States, which was estimated in 2012 at $245 billion.

Jardiance, which was approved in Europe in May of this year, was late in coming because of certain issues raised by the FDA at Boerhringer's manufacturing plant.

ADA 74th Scientific Sessions

Peer Exchange: Recorded during Patient-Centered Diabetes Care, Princeton, N.J., April 10, 2014.

American College of Cardiology 2014

This month's edition of Evidence-Based Diabetes Management, a news source of The American Journal of Managed Care, examines the science behind Mayor Michael Bloomberg's pursuit of soda portion limits, as well as alternatives for curtailing consumption to fight obesity. Soon after Mayor-elect de Blasio takes office, he must decide how to achieve Bloomberg's goal, including whether to continue litigation before the New York State Court of Appeals.

Drug Pipeline

With Science Reaching Consensus on Health Effects of Sugary Drinks, Talk of Portion Caps and Taxes Gains Steam Globally

Coverage of the 73rd Scientific Sessions of the American Diabetes Association.

With the unveiling of the first FDA-approved system with the name "artificial pancreas," Medtronic will seek a new CMS code that would cover both the insulin pump and the continuous glucose monitoring parts of the process, according to the company.

With speculation about an artificial pancreas rising, the September edition of Evidenced-Based Diabetes Management looked at the three systems that were being considered by the FDA including the threshold suspend technology Medtronic announced Friday and asked the next questions: Assuming the technology is approved, will insurers pay for it? How will this potentially life-altering advance make its way into the hands of the persons with diabetes who need it most?

Vets Study Shows Drop in Usage May Be Linked to Higher Glucose Levels; Former FDA Regulator, Leading Clinician Say 'Mea Culpa' Part of Cautionary Tale

Andrew J. M. Boulton, MD, describes the impact of non-invasive glucose monitoring devices on adherence and hospital admission rates.